These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22166802)

  • 1. Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems.
    Lamb GW; Aitchison M; Ramsey S; Housley SL; McMillan DC
    Br J Cancer; 2012 Jan; 106(2):279-83. PubMed ID: 22166802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer.
    Ramsey S; Lamb GW; Aitchison M; McMillan DC
    BJU Int; 2008 Apr; 101(8):959-63. PubMed ID: 18190639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy.
    Tsujino T; Komura K; Matsunaga T; Yoshikawa Y; Takai T; Uchimoto T; Saito K; Tanda N; Oide R; Minami K; Uehara H; Jeong SH; Taniguchi K; Hirano H; Nomi H; Ibuki N; Takahara K; Inamoto T; Azuma H
    Ann Surg Oncol; 2017 Sep; 24(9):2787-2793. PubMed ID: 28643013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of modified Glasgow Prognostic Score in patients with non-metastatic clear cell renal cell carcinoma.
    Cho DS; Kim SI; Choo SH; Jang SH; Ahn HS; Kim SJ
    Scand J Urol; 2016 Jun; 50(3):186-91. PubMed ID: 26878156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leibovich score is the optimal clinico-pathological system associated with recurrence of non-metastatic clear cell renal cell carcinoma.
    Blackmur JP; Gaba F; Fernando D; Williams S; O'Donnell M; McNeill A; Stewart GD; Leung S; Laird A
    Urol Oncol; 2021 Jul; 39(7):438.e11-438.e21. PubMed ID: 34023196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma.
    Higgins MI; Martini DJ; Patil DH; Nabavizadeh R; Steele S; Williams M; Joshi SS; Narayan VM; Sekhar A; Psutka SP; Ogan K; Bilen MA; Master VA
    Cancer; 2021 Jun; 127(12):1974-1983. PubMed ID: 33760232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma.
    Ficarra V; Novara G; Galfano A; Brunelli M; Cavalleri S; Martignoni G; Artibani W
    BJU Int; 2009 Jan; 103(2):165-70. PubMed ID: 18782313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated staging systems for conventional renal cell carcinoma: a comparison of two prognostic models.
    Martella O; Galatioto GP; Necozione S; Pomante R; Vicentini C
    Arch Ital Urol Androl; 2011 Sep; 83(3):121-7. PubMed ID: 22184835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.
    Cindolo L; Patard JJ; Chiodini P; Schips L; Ficarra V; Tostain J; de La Taille A; Altieri V; Lobel B; Zigeuner RE; Artibani W; Guillé F; Abbou CC; Salzano L; Gallo C
    Cancer; 2005 Oct; 104(7):1362-71. PubMed ID: 16116599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of the role of inflammation in renal cancer.
    Qayyum T; McArdle PA; Lamb GW; Going JJ; Orange C; Seywright M; Horgan PG; Oades G; Aitchison MA; Edwards J
    Urol Int; 2012; 88(3):277-81. PubMed ID: 22377628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma.
    Tan MH; Kanesvaran R; Li H; Tan HL; Tan PH; Wong CF; Chia KS; Teh BT; Yuen J; Chong TW
    Urology; 2010 Jun; 75(6):1365-1370; 1370.e1-3. PubMed ID: 20022084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The radiomics-based tumor heterogeneity adds incremental value to the existing prognostic models for predicting outcome in localized clear cell renal cell carcinoma: a multicenter study.
    Yang G; Nie P; Yan L; Zhang M; Wang Y; Zhao L; Li M; Xie F; Xie H; Li X; Xiang F; Wang N; Cheng N; Zhao X; Wang N; Wang Y; Chen C; Yun C; Cui J; Duan S; Zhang R; Hao D; Wang X; Wang Z; Niu H
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2949-2959. PubMed ID: 35344062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models.
    Westerman ME; Shapiro DD; Tannir NM; Campbell MT; Matin SF; Karam JA; Wood CG
    BJU Int; 2020 Dec; 126(6):745-753. PubMed ID: 32623821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer.
    Lamb GW; McMillan DC; Ramsey S; Aitchison M
    Br J Cancer; 2006 Mar; 94(6):781-4. PubMed ID: 16523196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of recurrence after nephrectomy: Comparison of predictive ability of validated risk models.
    Palumbo C; Perri D; Zacchero M; Bondonno G; Martino JD; D'Agate D; Volpe A
    Urol Oncol; 2022 Apr; 40(4):167.e1-167.e7. PubMed ID: 35034803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Expression of Mucin-4 Predicts Poor Prognosis in Patients With Clear-Cell Renal Cell Carcinoma.
    Fu H; Liu Y; Xu L; Chang Y; Zhou L; Zhang W; Yang Y; Xu J
    Medicine (Baltimore); 2016 Apr; 95(17):e3225. PubMed ID: 27124015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma.
    Liu Z; Liu Y; Xu L; An H; Chang Y; Yang Y; Zhang W; Xu J
    Cancer Sci; 2015 Sep; 106(9):1224-31. PubMed ID: 26179886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic Evaluation of the Modified Glasgow Prognostic Scale in Patients With Resected, Localized Clear Cell Renal Cell Carcinoma.
    Patil D; Le TL; Bens KB; Alemozaffar M; Lay A; Pattaras J; Filson CP; Ogan K; Bilen MA; Master VA
    Urology; 2020 Jul; 141():101-107. PubMed ID: 32294483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients.
    Parker WP; Cheville JC; Frank I; Zaid HB; Lohse CM; Boorjian SA; Leibovich BC; Thompson RH
    Eur Urol; 2017 Apr; 71(4):665-673. PubMed ID: 27287995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.